trial

Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure

NCTId NCT05603104
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 1,254 (estimated)
Sponsored by Dr. Inge Winter
Primary completion 2028-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
1,254 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2025-04-27
Primary completion
2028-06-30
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
Esketamine hydrochlorideBupropionClozapineEsketamine Nasal ProductescitalopramSertralineVenlafaxineLithiumValproate acidQuetiapineSecond-line AntidepressantsSecond-line AntipsychoticsKetamine Hydrochloride

Sponsors

Dr. Inge WinterLead Sponsor
Universität MünsterCollaborator

Sites

1 total
Ramat Gan, Israel

Linked catalysts

1
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disord — primary completion2028-06-30

Facts & assertions

4 sourced
Enrollment
1,254
Phase
PHASE3
Primary Completion Date
2028-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Esketamine hydrochloride
drug
Bupropion
drug
Clozapine
drug
Esketamine Nasal Product
drug
escitalopram
drug
Sertraline
drug
Venlafaxine
drug
Lithium
drug
Valproate acid
drug
Quetiapine
drug
Second-line Antidepressants
drug
Second-line Antipsychotics
drug
Ketamine Hydrochloride
drug
lead_sponsor
Dr. Inge Winter
company
collaborator
Universität Münster
company
indication
Bipolar Disorder
indication
Major Depressive Disorder
indication
Depressive Disorder, Major
indication